BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16600647)

  • 1. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
    Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
    Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
    Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
    Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
    Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
    Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
    Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
    Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
    Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
    Condemi JJ
    Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
    Hanrahan JP; Grogan DR; Baumgartner RA; Wilson A; Cheng H; Zimetbaum PJ; Morganroth J
    Medicine (Baltimore); 2008 Nov; 87(6):319-328. PubMed ID: 19011503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL
    Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
    Wang J; Nie B; Xiong W; Xu Y
    J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.